Predictors of vision-related quality of life in patients with macular oedema receiving intra-vitreal anti-VEGF treatment.

Petra T Rausch-Koster Katharina N Rennert Martijn W Heymans Frank D Verbraak Ger H M B van Rens Ruth Marie Antoinette van Nispen

Published in: Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) (2022)

Along with visual acuity of the better eye, which is the main factor used in clinical decision making, other patient characteristics should also be considered for the risk assessment of (Vr)QoL, such as sex, age, civil status, comorbidities and length of anti-VEGF treatment.

Keyphrases

risk assessment
decision making
endothelial cells
vascular endothelial growth factor
optical coherence tomography
case report
combination therapy
climate change
replacement therapy